Esra Polat

Dr. Esra Polat

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
SASadinaz Akdu
Sadinaz Akdu
ÜCÜmmügülsüm Can
Ümmügülsüm Can
EPEsra Polat
Esra Polat
OBJECTIVE: Hypertension is a major modifiable risk factor for cardiovascular disease and premature death worldwide. Phoenixin is a newly identified neuropeptide with multiple bioactivity. However, there was no published data about phoenixin levels in hypertension. The aim of this study was to evaluate the relationship between phoenixin and hypertension. METHODS: This study was performed in 36 patients with hypertension and 36 healthy controls. Serum phoenixin-14 and phoenixin-20 levels were RESULTS: Serum phoenixin-14 and phoenixin-20 values were significantly lower in hypertension patients compared with the control group (p<0.001). The levels of phoenixin-14 were negatively correlated with weight (r=-0.376; p<0.005), body mass index (r=-0.407; p<0.001), systolic blood pressure (r=-0.586; p<0.001), and diastolic blood pressure (r=-0.319; p<0.01). There was a negative correlation between serum phoenixin-20 and weight (r=0.378; p<0.005), body mass index (r=-0.383; p<0.005), systolic blood pressure (r=-0.551; p<0.001), and diastolic blood pressure (r=-0.306; p<0.01). We used receiver operating characteristic curve analyses to compare the diagnosis value of Phoenixin-14 and Phoenixin-20 levels in hypertensive patients. We found that Phoenixin-14 value is an area under the curve of 0.87 (cutoff value 404.7 ng/L, sensitivity 92%, specificity 72%) and Phoenixin-20 value is an area under the curve of 0.83 (cutoff value 209.9 ng/L, sensitivity 86%, specificity 75%). Phoenixin-14 did nearly show equally compared to phoenixin-20 in predicting hypertension. CONCLUSION: Serum phoenixin-14 and phoenixin-20 may be related to the pathogenesis of hypertension. Our findings indicated that serum phoenixin-14 and phoenixin-20 may serve as a novel biomarker for the diagnosis of hypertension.

14 June 2024 in Experimental and Applied Medical Science
Verified
Journal Article
Open access
LALutfu Askin
Lutfu Askin
EPEsra Polat
Esra Polat
YHYusuf HOSOGLU
Yusuf HOSOGLU
OTOkan Tanrıverdi
Okan Tanrıverdi
Artificial intelligence (AI) is used in the field of medicine to retrieve information from large databases by using advanced computer algorithms. AI has the potential to accelerate the identification and management of cardiovascular diseases (CVDs), including conditions such as heart failure, atrial fibrillation, valvular heart disease, hypertrophic cardiomyopathy, congenital heart disease, and several others. From a clinical perspective, AI enhances the diagnosis of CVD, increases the usefulness of auxiliary tools, aids in stratifying and identifying different types of diseases, and enables accurate prediction of outcomes. State-of-the-art AI algorithms, designed to extract minute connections from extensive healthcare data, are anticipated to address more challenging tasks compared to earlier methods. The goal of this research is to emphasize the current uses of AI in CVDs, thereby equipping doctors with little knowledge in computer science to gain a deeper understanding and effectively use AI algorithms in clinical practice.

30 April 2021 in Düzce Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
PDF file
MDMehmet Cihat Demir
Mehmet Cihat Demir
MDMuharrem Doğan
Muharrem Doğan
EPEsra Polat
Esra Polat
GAGüleser Akpınar
Güleser Akpınar
Aim: Atrial fibrillation (AF) is the most widespread persistent cardiac arrhythmia in adults. There is no standard procedure applied in AF patients with rapid ventricular response with unknown ejection fraction (EF) in the emergency department. This study aimed to compare the effectiveness and side effects of diltiazem and metoprolol treatments without knowing the EF in AF patients with rapid ventricular response in the emergency department. Material and Methods: Patients with a ventricular response ≥110/min were selected as having AF with rapid ventricular response. The patients first received 25 mg intravenous diltiazem as a rate control drug were compared with those first received 5 mg metoprolol. A total of 50 patients whose EF were not registered before the admission date and was measured after being consulted for cardiology following acute rate control in emergency department were included in this study. Results: For the first drug treatment, diltiazem was given to 56% (n=28) of the patients and metoprolol to 44% (n=22). Moreover, 44% (n=22) of the patients needed a second drug infusion. The proportion of patients received diltiazem in those with preserved EF was significantly higher than those with reduced EF (p=0.032). No statistically significant difference was found between the rates of needing a second administration based on the EF (p=0.157). Conclusion: Diltiazem was found to reduce heart rate earlier than metoprolol. While updating the guidelines for drug selection in acute rate control of AF with rapid ventricular response, rural emergency departments, where EF measurement cannot be achieved, should also be considered.

15 May 2023 in Medical Records
Verified
Journal Article
Open access
PDF file
FUFatma Yekta Urkmez
Fatma Yekta Urkmez
OEOzlem Erol
Ozlem Erol
EPEsra Polat
Esra Polat
SKSedat Kaygusuz
Sedat Kaygusuz
Aim: Real-time reverse transcription polymerase chain reaction (RT-PCR) test is used in the diagnosis of COVID-19. It was aimed to evaluate the factors affecting the viral conversion time, to examine the relationship between viral load, and to determine other factors that may be associated with viral load. Material and Methods: Patients were hospitalized between 15.03.2020-01.08.2020, and viral conversion detected were evaluated retrospectively. Patients were divided into two according to viral conversion time (0-14 days vs >14 days). Results: 349 patients were included in the study (284 vs 65 patients). The age and gender characteristics were similar. Prolonged PCR positivity group had more death (p=0.036) and lower cycle-threshold (CT) value (p=0.017). In the examination of CT values of 246 patients, 228 patients with viral conversion and 18 patients without viral conversion due to death, the CT value was found to be lower, therefore the viral load was higher in patients over 60 years of age (p=0.006), in the presence of cardiovascular system disease (p<0.001) and in patients who died (p<0.001). Conclusion: Prolonged PCR positivity may indicate excess viral load and adverse outcomes. An evaluation including the patient's age, CT value, comorbid conditions, and viral conversion time can give an idea about the prognosis.

19 October 2025 in Ankyra Medical Journal
Verified
Journal Article
Open access
PDF file
EEElif Eygi
Elif Eygi
SSSedat Sakallı
Sedat Sakallı
BDBilge Durucu
Bilge Durucu
EDEngin Dondurmacı
Engin Dondurmacı
FIFulden Akyüz İnAnç
Fulden Akyüz İnAnç
EPEsra Polat
Esra Polat
Aims: This study aimed to investigate whether the CALLY index is associated with mortality in patients admitted to intensive care due to decompensated heart failure. Methods: In this retrospective study, 130 patients diagnosed with decompensated heart failure admitted to the intensive care unit between 15 October 2023 and 15 October 2024 were included. Demographic data, comorbidities, stages of heart failure, length of stay in the intensive care unit, and mortality status were examined. CALLY index were calculated, and their relationship with mortality was examined. Results: The CALLY index was found to be statistically significant in distinguishing mortality (p = 0.018). A higher mortality rate was observed in the group with a low CALLY index (<=0.12) (% 26.9% vs % 10.3%) (p=0.013). Conclusion: In patients with decompensated heart failure followed in the intensive care unit, mortality was inversely related to the CALLY index. The CALLY index, a straightforward method for calculation, can serve as a guide for clinicians in determining prognosis.

15 March 2022 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
EPEsra Polat
Esra Polat
IIİbrahim Halil İnanç
İbrahim Halil İnanç
CSCengiz Sabanoglu
Cengiz Sabanoglu
Aim: The susceptibility to gastrointestinal bleeding is observed with an increase in altitude. There is no recommendation regarding altitude in terms of drug selection and dose to be used in diseases requiring antiaggregant and anticoagulant use. In this study, we aimed to determine whether there is a difference between gastrointestinal bleeding requiring hospitalization due to the use of antiaggregant and/or anticoagulant therapy between two populations living at different altitudes. Material and Method: This retrospective study was performed in two secondary care hospitals. Patients from Group B living in villages with an altitude of 9842 ft and above and Group F patients living in an area with an altitude of 30 ft were included. Patient’s demographic data, co-morbid diseases, antiaggregant and anticoagulant use, hemoglobin, hematocrit, MCV values and platelet count were noted. Results: The study included a total of 118 patients with gastrointestinal bleeding. There was no statistically significant difference between the groups in terms of the drugs used by the patients, the types and numbers of drugs. Conclusion: We found that there was no significant difference between the groups with different altitudes in terms of drugs used by patients with gastrointestinal bleeding, drug types and numbers.